NCT01414101 is a Phase 2 clinical trial of ISIS CRP Rx or Placebo in Rheumatoid Arthritis, sponsored by Ionis Pharmaceuticals, Inc..

Who is sponsoring NCT01414101?

NCT01414101 is sponsored by Ionis Pharmaceuticals, Inc..

What drugs are being tested in NCT01414101?

Interventions in NCT01414101: ISIS CRP Rx or Placebo.

What condition does NCT01414101 study?

NCT01414101 studies Rheumatoid Arthritis.

Is NCT01414101 still recruiting?

NCT01414101 is currently completed. Last updated 16 May 2013.

Last reviewed 2013-05-16 · How we verify

NCT01414101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis

Completed Phase 2 Last updated 16 May 2013

What this trial tests

Phase 2 trial testing ISIS CRP Rx or Placebo in Rheumatoid Arthritis in 51 participants. Completed in 1 May 2013.

Timeline

1 August 2011

Primary endpoint
1 May 2013

1 May 2013

Quick facts

Lead sponsor	Ionis Pharmaceuticals, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	51
Start date	1 August 2011
Primary completion	1 May 2013
Estimated completion	1 May 2013
Sites	10 locations across Canada, Russia

Drugs / interventions tested

ISIS CRP Rx or Placebo — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Ionis Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety
Time frame: 155 Days
Adverse events, laboratory tests, and vital signs

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ISIS CRP Rx and its effects on CRP and other pharmacodynamic measures, versus placebo, in subjects with active rheumatoid arthritis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.
Zeller J, Cheung Tung Shing KS, Nero TL, McFadyen JD, et al · · 2023 · cited 43× · PMID 36468184 · DOI 10.15252/emmm.202216236
Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis.
Warren MS, Hughes SG, Singleton W, Yamashita M, et al · · 2015 · cited 21× · PMID 25885521 · DOI 10.1186/s13075-015-0578-5

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Ionis Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06673069 — Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Par · Phase 1 · terminated
NCT06014541 — Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 · terminated
NCT05610280 — A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, · Phase 3 · completed
NCT05579860 — A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healt · Phase 1 · completed
NCT05552326 — A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01414101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ionis Pharmaceuticals, Inc.
Last refreshed: 16 May 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01414101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing